Orrick represented Ipsen in the transaction. Ipsen, a global biopharmaceutical company with a focus on bringing transformative medicines to patients in oncology, rare diseases and neuroscience,...
You must be a Standard 1 Year member to access this content.
Clifford Chance acted for Ipsen Pharma GmbH. Ipsen Pharma GmbH has filed a constitutional complaint against the provisions of the latest “austerity laws”, i.e., the Act on...
You must be a Standard 1 Year member to access this content.
Orrick and Cirio advised Ipsen on the deal, while Paul, Weiss, Rifkind, Wharton & Garrison and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo advised Albireo. Ipsen...
You must be a Standard 1 Year member to access this content.
Orrick Herrington & Sutcliffe advised Ipsen on the deal. Global biopharmaceutical company Ipsen (Euronext: IPN; ADR: IPSEY) announced its definitive agreement to acquire Epizyme (Nasdaq: EPZM), a...
You must be a Standard 1 Year member to access this content.
Deloitte | Taj et M&A Transaction Services and Dechert advised Mayoly Spindler, while Allen & Overy advised Ipsen. Weil Gotshal & Manges advised Caravelle and Capza...
You must be a Standard 1 Year member to access this content.
